NextBioMedical: 2026 Q1 Revenue Up, Loss Narrows

2026 Q1 revenue KRW 4.12bn (up 9.2% YoY from KRW 3.77bn)
Net loss KRW 0.15bn (narrowed 65% from KRW 0.42bn YoY)
R&D expenses KRW 2.08bn (51% of revenue), including stock compensation of KRW 1.03bn
Cash and cash equivalents KRW 4.02bn (down from KRW 6.79bn at year-end 2025)
Total borrowings KRW 7.33bn (short-term KRW 2.16bn, long-term KRW 5.17bn)
Debt-to-equity ratio 22.3% (improved from 23.2%)
Nexsphere-F US FDA pivotal clinical trial ongoing, Breakthrough Device designation
Nexpowder approved in Japan (PMDA Feb 2025), UKCA, Brazil
No shareholder return (buyback/dividend) disclosed